Introduction {#section4-1947603510363005}
============

Bone formation is the process by which mesenchymal cells condense at specific sites and differentiate into chondrocytes, forming the cartilage anlagen that are the model for future bone. These cells undergo an ordered differentiation program: The chondrocytes proliferate, become prehypertrophic, and then undergo hypertrophy. The mature cartilage undergoes calcification, known as ossification. Each step of cartilage maturation occurs in a precise and tightly regulated manner, and disruption of this process can cause abnormalities in cartilage and bone formation.^[@bibr1-1947603510363005],[@bibr2-1947603510363005]^

Homeobox genes of the Hox class are required for proper patterning of elements in the developing skeleton.^[@bibr3-1947603510363005]-[@bibr5-1947603510363005]^ They also play a role in the regulation of cartilage differentiation prior to overt bone formation.^[@bibr6-1947603510363005]-[@bibr8-1947603510363005]^ Misexpression and overexpression studies suggested that Hox genes affect the size of cartilage condensations and chondrocyte proliferation.^[@bibr3-1947603510363005],[@bibr8-1947603510363005]-[@bibr10-1947603510363005]^ We recently demonstrated a role for Hoxc8 in cell cycle regulation in primary chondrocytes.^[@bibr11-1947603510363005]^

Transgenic mice with overexpression of Hoxc8 and Hoxd4 under control of the Hoxc8 promoter exhibit profound cartilage defects, predominately in the ribs and vertebral column, and the severity of defects is dependent on transgene dosage.^[@bibr10-1947603510363005]^ The abnormal cartilage is characterized by an accumulation of proliferating chondrocytes and reduced cartilage maturation. The cartilage of the ribs in transgenic mice remains weak and is structurally insufficient, resulting in pulmonary failure and death shortly after birth.^[@bibr8-1947603510363005],[@bibr10-1947603510363005]^ Thus, Hox genes are important regulators of chondrocyte proliferation and maturation.

However, it is not well understood how Hox transcription factors control the process of chondrogenesis or which target genes they may regulate in chondrocytes. The aim of these studies was to identify genes with altered expression in the Hoxc8- and Hoxd4-transgenic paradigms as a first step toward determining the transcriptional targets of Hox transcription factors in cartilage differentiation and maturation.

Materials and Methods {#section5-1947603510363005}
=====================

Animals {#section6-1947603510363005}
-------

Animals used in this work were created by the VP16-dependent binary system^[@bibr12-1947603510363005]^ for expression of Hoxc8 and Hoxd4 transgenes. In brief, the binary transgenic system is based on the potent transcriptional activator VP16 of herpes simplex virus (HSV). One line, the transactivator (TA), harbors the transgene encoding VP16 under the control of the promoter from the Hoxc8 gene,^[@bibr7-1947603510363005],[@bibr10-1947603510363005]^ which is active in cartilage precursor cells (C. Kappen, unpublished data). The other line, the transresponder (TR), harbors a Hox transgene under the control of the HSV ICP4 gene immediate early promoter. Activation of the immediate early promoter requires the presence of VP16 protein; hence, transgene expression is achieved only in individuals carrying both the TA and TR transgenes.^[@bibr13-1947603510363005]^ Here, we classify progeny by 2 genotypes: the control genotype (TA), containing at least one TA and no TR transgene, and the experimental genotype (TA+TR), containing at least one TA and one TR transgene. All transgenes were maintained on an FVB inbred genetic background. The characterizations of the phenotypes of both transgenic lines^[@bibr8-1947603510363005],[@bibr10-1947603510363005]^ and the levels of expression for Hox transgenes in transgenic chondrocytes^[@bibr14-1947603510363005]^ have been published.

Pregnant dams were sacrificed at 18.5 days of gestation. Double transgenic embryos are phenotypically identifiable by failure of eyelid closure,^[@bibr8-1947603510363005],[@bibr10-1947603510363005]^ and for confirmation, genotyping was performed on DNA isolated from tails of individual specimen.^[@bibr13-1947603510363005]^ Transgene expression in all samples was demonstrated by quantitative reverse transcriptase polymerase chain reaction (RT-PCR) as described earlier.^[@bibr14-1947603510363005]^

RNA and cDNA Preparation {#section7-1947603510363005}
------------------------

Embryos were collected at day 18.5 of gestation, and individual rib cages were dissected. Rib cages from the same litter were pooled according to genotype, and rib chondrocytes were prepared as described.^[@bibr15-1947603510363005]^ Freshly isolated cells were immediately transferred into Trizol reagent (Invitrogen, Carlsbad, CA), and total RNA was isolated and purified as described previously.^[@bibr14-1947603510363005]^ Quality of RNA was assessed using the Agilent 2100 bioanalyzer (Agilent Technologies, Santa Clara, CA), and quantity was determined in the NanoDrop ND-1000 Spectrophotometer (NanoDrop Technologies, Rockland, DE). Complementary DNA was obtained by reverse transcription (SuperScript III First-Strand Synthesis System for RT-PCR; Invitrogen, Carlsbad, CA) of 3 µg of RNA from each sample. This reaction used both Oligo(dT)~20~ and random hexamers as primers; all further steps were done following the supplier's instructions (Invitrogen). Purification of cDNA was performed using QIAquick PCR purification columns (Qiagen, Valencia, CA).

Microarray Analysis {#section8-1947603510363005}
-------------------

A total of 16 samples (4 controls and 4 Hoxc8-transgenic samples, and 4 controls and 4 Hoxd4-transgenic samples, respectively) were hybridized to individual Affymetrix GeneChip Mouse Genome 430 2.0 arrays. Probe labeling, hybridization, washing, and scanning were performed according to Affymetrix's protocol using a GenePix4000 scanner. Data sets were analyzed using GCOS software for background normalization, and each probe set (entity) was assigned an expression call (P = present, M = marginal, A = absent). CHP files were loaded into GeneSpring GX10 software (Agilent Technologies) using default parameters. Entities that were assigned "present" or "marginal" for 5 of 8 samples underwent an unpaired *t*-test with false discovery rate set at 0.05 (the Gene Spring default setting was used for multiple testing correction). Entities satisfying the *P*-value cutoff of *P* ≤ 0.05 and fold-change ≥ 1.5 were saved in separate lists for further analysis. In parallel, the microarray results were analyzed using CyberT (<http://cybert.microarray.ics.uci.edu/>), which gave essentially identical results. Hierarchical clustering was performed in GeneSpring GX10, using the K-means method with Euclidean distance metric; 3 clusters were revealed after 50 iterations.

Annotations for probe set ID numbers were taken as provided by Affymetrix and were further hand curated by comparison to the Mouse Genome Informatics database (<http://www.informatics.jax.org>)

Quantitative Real-Time PCR Assays {#section9-1947603510363005}
---------------------------------

The MultiPROBE II PLUS HT EX robot (Perkin Elmer, Shelton, CT) was programmed to pipette 10-µL reactions into an Applied Biosystems (Foster City, CA) 384-well plate. The robot adds 3 µL template (1.6 ng cDNA) and 7 µL Master Mix (5 µL iTaq SYBR Green Supermix with ROX, 0.1 µL forward primer 10 µM, 0.1 µL reverse primer 10 µM, 1.8 µL NanoPure water) per reaction. The iTaq SYBR Green Supermix with ROX (2X) was obtained from Bio-Rad Laboratories (Hercules, CA). The cDNA template and the Master Mix were provided in a 96-well optical plate. Gene expression levels were measured using the ABI PRISM 7900HT Sequence Detection System with SDS 2.2.2 software version (Applied Biosystems). Individual samples were run in triplicate. The thermal cycler conditions consisted of 1 cycle of 2 min at 50 °C, one cycle of 10 min at 95 °C, followed by 40 cycles at 95 °C for 15 s and 1 min at 60 °C.

Primers for amplification were designed using Primer Express 3 software (Applied Biosystems) with default settings. Primers for the gene Gapdh were used as provided by Applied Biosystems. The sequences of primer pairs used in this work are listed in Supplemental Table S1. To exclude amplification of potentially contaminating genomic DNA, primers were designed to span an exon/exon junction where possible. Each primer pair was validated by melting point analysis under conditions of a programmed temperature ramp of 15 s at 95 °C, 15 s at 60 °C, and 15 s at 95 °C, monitoring the hybridization activity of nucleic acids present in the sample, and by PCR on cDNA derived from pooled RNA of E10.5 mouse embryos.

Amplification efficiencies were determined for each gene-specific reaction over the first 3 cycles above the threshold of detection by using the formula ΔRn~cycle(n)~/ΔRn~cycle(n-1)~, averaged over the triplicates for each sample. Relative quantification was done using the Comparative C~T~ method with actual amplification efficiency to produce the relative fold-change in expression level between transgenic and control.^[@bibr14-1947603510363005],[@bibr16-1947603510363005]^ For quantitative RT-PCR, at least 6 samples each were used for the Hoxc8- and Hoxd4-transgenics and their control littermates, respectively (*n* = 6 for each condition).

Statistical Analysis {#section10-1947603510363005}
--------------------

Statistical analysis was performed by *t*-tests and analysis of variance to evaluate significance of differences in gene expression between controls and Hoxc8-transgenic or controls and Hoxd4-transgenic samples, respectively. *P* values of \< 0.05 were considered statistically significant.

Results {#section11-1947603510363005}
=======

Gene Expression in Hoxc8-Transgenic Cartilage {#section12-1947603510363005}
---------------------------------------------

To discover genes that potentially exhibit deregulated expression in cartilage of mice overexpressing Hoxc8, we conducted genomewide expression profiling in primary chondrocytes using the Affymetrix Mouse 430 2.0 platform. Of 45,101 entities arrayed on the chips, 58 entities passed the fold-change ≥ 1.5 and *P* value \< 0.05 criteria when samples from transgenic mice were compared with controls (**[Table 1](#table1-1947603510363005){ref-type="table"}**). Two probe sets lack annotation for gene or locus. The expression level of 27 entities (26 genes) was significantly elevated in Hoxc8-transgenic samples compared with the control group, whereas 31 entities (containing 2 probe sets for Zbtb3; 29 genes) exhibited decreased expression in Hoxc8-transgenic samples. Differences in expression levels ranged between 1.5- and 2.5-fold. An independent statistical analysis of our Hoxc8 data sets was performed using CyberT on raw hybridization intensity values; this identified the same group of genes found by GeneSpring.

###### 

Differentially Expressed Genes in Hoxc8-Transgenic Chondrocytes

  Probe set ID    Gene symbol     Gene title                                                                  Fold-change   Transgenic/control   *P* value
  --------------- --------------- --------------------------------------------------------------------------- ------------- -------------------- -----------
  1430756_at      5430427G11Rik   RIKEN cDNA 5430427G11 gene                                                  1.97          Up                   0.0000931
  1433377_at      5830445D09Rik   RIKEN cDNA 5830445D09 gene                                                  1.73          Up                   0.0439948
  1437076_at      A930017M01Rik   RIKEN cDNA A930017M01 gene                                                  1.60          Up                   0.0040773
  1446095_at      Airn            Antisense Igf2r RNA                                                         1.51          Up                   0.0407707
  1417470_at      Apobec3         Apolipoprotein B editing complex 3                                          1.66          Up                   0.0385239
  1420120_at      AU020177        Expressed sequence AU020177                                                 1.79          Up                   0.0268048
  1435909_at      C030034I22Rik   RIKEN cDNA C030034I22 gene                                                  1.55          Up                   0.0157238
  1457749_at      Cc2d1b          Coiled-coil and C2 domain containing 1B                                     1.67          Up                   0.0259771
  1417936_at      Ccl9            Chemokine (C-C motif) ligand 9                                              1.61          Up                   0.0071056
  1429976_at      Clasp2          CLIP associating protein 2                                                  1.58          Up                   0.0231768
  1437654_at      Fam35a          Family with sequence similarity 35, member A                                1.53          Up                   0.0354986
  1443628_at      Fam82b          Family with sequence similarity 82, member B                                1.79          Up                   0.0257141
  1457228_x\_at   Gle1            GLE1 RNA export mediator (yeast)                                            1.52          Up                   0.0200380
  1453855_at      Mxra7           Matrix-remodeling associated 7                                              1.80          Up                   0.0276739
  1439999_at      NA              NA                                                                          1.75          Up                   0.0055803
  1457117_at      Nfe2l2          Nuclear factor, erythroid derived 2, like 2                                 1.62          Up                   0.0351502
  1432539_a\_at   Nup54           Nucleoporin 54                                                              1.51          Up                   0.0157982
  1455145_at      Pcdh19          Protocadherin 19                                                            1.53          Up                   0.0408313
  1456955_at      Pppde1          PPPDE peptidase domain containing 1                                         1.67          Up                   0.0098931
  1436569_at      Prex2           Pphosphatidylinositol-3,4,5-trisphosphate-dependent Rac exchange factor 2   1.55          Up                   0.0192962
  1451560_at      Prr12           Pproline rich 12                                                            1.53          Up                   0.0217165
  1434043_a\_at   Repin1          Replication initiator 1                                                     1.69          Up                   0.0474017
  1442044_at      Rps6            Ribosomal protein S6                                                        1.56          Up                   0.0169256
  1428216_s\_at   Tomm7           Translocase of outer mitochondrial membrane 7 homolog (yeast)               1.52          Up                   0.0391876
  1459672_at      Top1            Topoisomerase (DNA) I                                                       1.68          Up                   0.0010994
  1455722_at      Wasf3           WAS protein family                                                          1.51          Up                   0.0030891
  1429474_at      Zadh1           Zinc binding alcohol dehydrogenase                                          1.64          Up                   0.0445114
  1443902_at      6430573F11Rik   RIKEN cDNA 6430573F11 gene                                                  1.72          Down                 0.0341196
  1437940_at      Apba1           Amyloid beta (A4) precursor protein binding                                 1.55          Down                 0.0198718
  1449356_at      Asb5            Ankyrin repeat and SOCs box-containing protein 5                            1.56          Down                 0.0289805
  1442207_at      Atg16l2         Autophagy related 16 like 2 (S. cerevisiae)                                 1.55          Down                 0.0119739
  1443337_at      B130020M22Rik   0 day neonate lung cDNA                                                     1.56          Down                 0.0227655
  1452966_at      Bcl11b          B-cell leukemia/lymphoma 11B                                                1.77          Down                 0.0115030
  1418777_at      Ccl25           Chemokine (C-C motif) ligand 25                                             1.58          Down                 0.0356987
  1443746_x\_at   Dmp1            Dentin matrix protein 1                                                     1.92          Down                 0.0201768
  1446431_at      Dnm3            Dynamin                                                                     1.70          Down                 0.0378060
  1434714_at      Ero1lb          ERO1-like beta (S. cerevisiae)                                              1.53          Down                 0.0312197
  1440359_at      Fam110b         Family with sequence similarity 110, member B                               1.54          Down                 0.0340775
  1453689_at      Fance           Fanconi anemia                                                              1.84          Down                 0.0054524
  1450319_at      Gabrb2          Gamma-aminobutyric acid (GABA-A) receptor                                   1.51          Down                 0.0367941
  1438152_at      Gpaa1           GPI anchor attachment protein 1                                             2.00          Down                 0.0375435
  1419196_at      Hamp            Hepcidin antimicrobial peptide                                              2.16          Down                 0.0399568
  1444709_at      Invs            Inversin                                                                    1.93          Down                 0.0246062
  1446131_at      Jam3            Junction adhesion molecule 3                                                1.58          Down                 0.0347649
  1425104_at      Kctd1           Potassium channel tetramerisation domain containing 1                       2.12          Down                 0.0020032
  1454845_x\_at   Mchr1           Melanin-concentrating hormone receptor 1                                    1.66          Down                 0.0210230
  1443267_at      NA              NA                                                                          1.57          Down                 0.0433589
  1438614_x\_at   Osbpl9          Oxysterol binding protein-like 9                                            2.04          Down                 0.0058520
  1426753_at      Phf17           PHD finger protein 17                                                       1.66          Down                 0.0481360
  1439508_at      Rab11b          RAB11B                                                                      1.71          Down                 0.0289390
  1459315_at      Rab5c           RAB5C, member RAS oncogene family                                           1.92          Down                 0.0172757
  1452862_at      Rreb1           ras responsive element binding protein 1                                    1.53          Down                 0.0402444
  1428794_at      Specc1          Sperm antigen with calponin homology and coiled-coil domains 1              1.69          Down                 0.0072438
  1446680_at      Stag1           Stromal antigen 1                                                           2.48          Down                 0.0070552
  1416927_at      Trp53inp1       Transformation related protein 53 inducible nuclear protein 1               1.60          Down                 0.0446587
  1447894_x\_at   Vps52           Vacuolar protein sorting 52 (yeast)                                         1.56          Down                 0.0230638
  1427106_at      Zbtb3           Zinc finger and BTB domain containing 3                                     1.61          Down                 0.0168218
  1440180_x\_at   Zbtb3           Zinc finger and BTB domain containing 3                                     1.58          Down                 0.0101039

Note: Affymetrix probe set ID numbers are given for representative probe sets; Zbfb3 is represented by 2 probe sets, and 1 probe set has no annotation. The comparison of transgenic/control indicates elevation or reduction of expression in Hoxc8-transgenic chondrocytes relative to controls. Fifty-eight entities (57 genes) are differentially expressed (unpaired *t*-test; fold-change ≥1.5; *P* value \< 0.05) in Hoxc8-transgenic chondrocytes compared with controls.

For visualization of gene expression profiles, we used the K-means clustering algorithm. The analysis grouped the entities listed in **[Table 1](#table1-1947603510363005){ref-type="table"}** into 3 clusters, pictured in **[Figure 1](#fig1-1947603510363005){ref-type="fig"}** (**[Fig. 1A](#fig1-1947603510363005){ref-type="fig"}**). The first 2 clusters contain genes with expression levels higher (red) or lower (blue) than the mean (white) over all 8 samples. Fourteen entities fall in the 3rd cluster, which represents moderate changes in expression level.

![Differential gene expression in Hoxc8- and Hoxd4-transgenic cartilage. K-means clustering algorithm and Euclidean distance metric (as implemented in GeneSpring) were used to visualize the different expression profiles for (**A**) Hoxc8 and (**B**) Hoxd4 transgenic chondrocytes relative to their controls. Columns 1 to 4 represent the control groups (transactivator-containing samples), and columns 5 to 8 display the transgenic groups (transresponder-containing samples). Fifty-eight entities for Hoxc8 and 85 entities for Hoxd4 passed the unpaired *t*-test ("present" or "marginal" flag in 5 of 8 samples, fold-change ≥ 1.5 and *P* value \< 0.05).](10.1177_1947603510363005-fig1){#fig1-1947603510363005}

Of 55 genes, 18 genes with a moderate to strong hybridization signal were chosen for validation by quantitative RT-PCR (**[Table 2](#table2-1947603510363005){ref-type="table"}**). A *P* value lower than 0.05 was found only for Gpaa1, but decreased expression in transgenic samples by more than 1.5-fold, as found by the microarray study, could not be confirmed.

###### 

Validation of Gene Expression by Quantitative Reverse Transcriptase Polymerase Chain Reaction CR in Hoxc8- and Hoxd4-Transgenic Chondrocytes

  Probe set ID    Gene symbol     ΔCt ± SD control   ΔCt ± SD Hoxc8-transgenic   Fold-change transgenic/control   *P* value
  --------------- --------------- ------------------ --------------------------- -------------------------------- -----------
  1430756_at      5430427G11Rik   11.56 ± 0.40       11.51 ± 0.45                1.03                             0.85403
  1433377_at      5830445D09Rik   13.35 ± 0.34       13.64 ± 0.84                --1.18                           0.45344
  1417470_at      Apobec3         7.58 ± 0.34        7.82 ± 0.22                 --1.16                           0.17429
  1418777_at      Ccl25           9.74 ± 0.49        9.78 ± 0.36                 --1.03                           0.86563
  1446431_at      Dnm3            7.25 ± 0.28        7.36 ± 0.42                 --1.05                           0.71857
  1437654_at      Fam35a          10.26 ± 0.64       10.36 ± 0.56                --1.07                           0.76193
  1453689_at      Fance           7.27 ± 0.27        7.27 ± 0.33                 1.00                             0.98538
  1457228_x\_at   Gle1            4.94 ± 0.24        5.06 ± 0.32                 --1.08                           0.48505
  1438152_at      Gpaa1           4.70 ± 0.32        4.91 ± 0.47                 --1.15                           0.04020
  1425104_at      Kctd1           13.07 ± 0.42       12.81 ± 1.00                1.16                             0.57281
  1454845_x\_at   Mchr1           13.54 ± 0.95       12.91 ± 0.64                1.41                             0.24740
  1436569_at      Prex2           9.35 ± 0.39        9.17 ± 0.61                 1.12                             0.54688
  1451560_at      Prr12           5.23 ± 0.60        5.37 ± 0.57                 --1.09                           0.68803
  1459315_at      Rab5c           12.55 ± 0.31       12.81 ± 0.62                --1.18                           0.37860
  1434043_a\_at   Repin1          7.94 ± 0.25        8.05 ± 0.16                 --1.08                           0.37954
  1428794_at      Specc1          9.05 ± 0.44        9.28 ± 0.36                 --1.16                           0.34507
  1446680_at      Stag1           4.94 ± 0.38        5.05 ± 0.27                 --1.07                           0.58376
  1427106_at      Zbtb3           7.58 ± 0.34        7.82 ± 0.22                 --1.16                           0.17429
                                  Control            Hoxd4-transgenic            Transgenic/control               
  1453358_s\_at   Amn1            8.89 ± 0.43        8.94 ± 0.54                 --1.03                           0.88327
  1421392_a\_at   Birc3           7.75 ± 0.39        7.54 ± 0.30                 1.15                             0.31514
  1439327_at      Ccbe1           9.98 ± 1.02        10.15 ± 0.91                --1.12                           0.76701
  1433956_at      Cdh5            6.73 ± 0.90        6.59 ± 0.75                 1.09                             0.78587
  1452077_at      Ddx3y           5.89 ± 0.75        5.12 ± 0.78                 --1.35                           0.76750
  1427462_at      E2f3            6.72 ± 0.42        6.51 ± 0.13                 1.15                             0.26012
  1417210_at      Eif2s3y         6.56 ± 0.77        5.85 ± 0.77                 1.58                             0.14367
  1416916_at      Elf3            11.13 ± 0.25       11.26 ± 0.29                --1.09                           0.42656
  1445191_at      Exd1            11.37 ± 0.48       11.68 ± 0.64                --1.24                           0.36159
  1437106_at      Kdm5a           5.04 ± 0.24        5.09 ± 0.16                 --1.04                           0.64603
  1456618_at      Mark4           7.03 ± 0.50        6.76 ± 0.27                 1.19                             0.27688
  1429715_at      Ppp2r2a         6.98 ± 0.45        6.79 ± 0.23                 1.12                             0.38864
  1460419_a\_at   Prkcb           12.36 ± 0.44       12.85 ± 0.66                --1.38                           0.15940
  1451995_at      Taf11           6.78 ± 0.50        6.87 ± 0.74                 -1.06                            0.81399
  1445668_at      Tbce            6.55 ± 0.20        6.35 ± 0.26                 1.14                             0.17103
  1450038_s\_at   Usp9x           3.73 ± 0.25        3.71 ± 0.22                 1.01                             0.88108
  1426598_at      Uty             8.73 ± 0.79        7.47 ± 0.63                 2.27                             0.01184
  1450151_at      Zfp316          9.15 ± 0.36        9.40 ± 0.86                 --1.18                           0.52654

Note: Six transgenic chondrocyte samples were compared with 6 control samples, and reactions were done in triplicates. ΔCt values were determined relative to the Ct value for Gapdh in the same sample. For each gene, the fold-change was calculated using the formula fold-change = AE^-ΔΔCt^ (AE = amplification efficiency; see Supplemental Table S1), where AE was calculated using the formula AE = ΔRn~cycle(n)~/ΔRn~cycle(n-1)~ over 3 cycles in the linear range of the reaction.

Gene Expression in Hoxd4-Transgenic Cartilage {#section13-1947603510363005}
---------------------------------------------

To identify genes whose expression may be deregulated by overexpression of Hoxd4 in cartilage, we conducted a separate genomewide expression profiling experiment using the same platform as before. Eighty-five entities displayed expression levels that were significantly changed by more than 1.5-fold in Hoxd4-transgenic chondrocytes relative to controls (**[Table 3](#table3-1947603510363005){ref-type="table"}**). These findings were confirmed when using CyberT as a statistical analysis tool. Two probe sets lack annotation. The majority of entities (50 genes) we identified were expressed at lower levels in Hoxd4-transgenic chondrocytes; 35 entities (28 genes) exhibited significantly elevated expression in Hoxd4-transgenic chondrocytes compared with control samples. Among this group, 2 genes (Ddx3y and Eif2s3y) were represented by 2 probe sets and Uty by 4 probe sets. Among the 78 differentially expressed transcripts, we identified 3 members of the solute carrier family (Slc25a32, Slc34a2, Slc46a1), 2 zinc finger proteins (Zfp69, Zfp316), 2 protein tyrosine phosphatases (Ptprb, Ptprd), and 2 cadherins (Chd5, Cdh10).

###### 

Differentially Expressed Genes in Hoxd4-Transgenic Chondrocytes

  Probe set ID    Gene symbol     Gene title                                                                        Fold-change   Transgenic/control   *P* value
  --------------- --------------- --------------------------------------------------------------------------------- ------------- -------------------- -----------
  1443346_at      2700007P21Rik   RIKEN cDNA 2700007P21 gene                                                        1.62          Up                   0.0043344
  1429510_at      2810410L24Rik   RIKEN cDNA 2810410L24 gene                                                        1.77          Up                   0.0466781
  1459145_at      A930033H14Rik   RIKEN cDNA A930033H14 gene                                                        1.51          Up                   0.0015565
  1449641_at      Adk             Adenosine kinase                                                                  1.63          Up                   0.0294934
  1434296_at      BC049349        cDNA sequence BC049349                                                            1.54          Up                   0.0099971
  1452503_a\_at   Brwd1           Bromodomain and WD repeat domain containing 1                                     2.00          Up                   0.0234259
  1447803_x\_at   Capg            Capping protein (actin filament)                                                  1.64          Up                   0.0271682
  1430605_at      Ccdc101         Coiled-coil domain containing 101                                                 1.51          Up                   0.0483277
  1435574_at      Chordc1         Cysteine and histidine-rich domain (CHORD)-containing                             1.92          Up                   0.0068320
  1421267_a\_at   Cited2          Cbp/p300-interacting transactivator                                               1.55          Up                   0.0249589
  1426438_at      Ddx3y           DEAD (Asp-Glu-Ala-Asp) box polypeptide 3                                          1.82          Up                   0.0410493
  1452077_at      Ddx3y           DEAD (Asp-Glu-Ala-Asp) box polypeptide 3                                          1.81          Up                   0.0428568
  1434789_at      Depdc1b         DEP domain containing 1B                                                          1.51          Up                   0.0075120
  1417210_at      Eif2s3y         Eukaryotic translation initiation factor 2, subunit 3, structural gene Y-linked   1.95          Up                   0.0113469
  1457945_at      Eif2s3y         Eukaryotic translation initiation factor 2, subunit 3, structural gene Y-linked   1.80          Up                   0.0285858
  1437791_s\_at   Eml5            Echinoderm microtubule associated protein like 5                                  1.62          Up                   0.0244599
  1441543_at      Eya3            Eyes absent 3 homolog (Drosophila)                                                2.05          Up                   0.0207881
  1460021_at      Gm6658          Predicted gene 6658                                                               1.50          Up                   0.0043136
  1449954_at      Hyal1           Hyaluronoglucosaminidase 1                                                        1.67          Up                   0.0171650
  1456618_at      Mark4           MAP/microtubule affinity-regulating kinase 4                                      2.20          Up                   0.0250543
  1440924_at      Mphosph1        M-phase phosphoprotein 1                                                          1.51          Up                   0.0244418
  1442153_at      NA              NA                                                                                1.87          Up                   0.0377096
  1438907_at      NA              NA                                                                                1.75          Up                   0.0080244
  1453139_at      Nudt12          Nudix (nucleoside diphosphate linked moiety X)-type motif 12                      1.61          Up                   0.0044737
  1424605_at      Pcsk5           Proprotein convertase subtilisin/kexin type 5                                     1.59          Up                   0.0161911
  1429715_at      Ppp2r2a         Protein phosphatase 2 (formerly 2A)                                               1.74          Up                   0.0266788
  1439960_at      Rpusd2          RNA pseudouridylate synthase domain containing 2                                  1.75          Up                   0.0102783
  1445668_at      Tbce            Tubulin-specific chaperone E                                                      1.82          Up                   0.0259176
  1450038_s\_at   Usp9x           Ubiquitin specific peptidase 9                                                    1.65          Up                   0.0004397
  1459565_at      Uty             Ubiquitously transcribed tetratricopeptide repeat gene                            2.18          Up                   0.0019270
  1457582_at      Uty             Ubiquitously transcribed tetratricopeptide repeat gene                            1.95          Up                   0.0087905
  1426598_at      Uty             Ubiquitously transcribed tetratricopeptide repeat gene                            1.91          Up                   0.0122254
  1422247_a\_at   Uty             Ubiquitously transcribed tetratricopeptide repeat gene                            1.53          Up                   0.0251188
  1458274_at      Zfp69           Zinc finger protein 69                                                            1.71          Up                   0.0088002
  1443105_at      Zfp398          Zinc finger protein 398                                                           1.69          Up                   0.0085782
  1422107_at      2410066E13Rik   RIKEN cDNA 2410066E13 gene                                                        1.63          Down                 0.0343780
  1442237_at      3010026O09Rik   RIKEN cDNA 3010026O09 gene                                                        1.61          Down                 0.0298389
  1430940_at      3110045A19Rik   RIKEN cDNA 3110045A19 gene                                                        1.58          Down                 0.0413230
  1431566_at      9030622O22Rik   RIKEN cDNA 9030622O22 gene                                                        1.64          Down                 0.0111243
  1432798_at      9530023I19Rik   RIKEN cDNA 9530023I19 gene                                                        1.96          Down                 0.0341054
  1453358_s\_at   Amn1            Antagonist of mitotic exit network 1 homolog (S. cerevisiae)                      1.55          Down                 0.0251336
  1443551_at      Atp2a2          ATPase                                                                            1.88          Down                 0.0125872
  1437310_at      Bbs1            Bardet-Biedl syndrome 1 homolog (human)                                           1.50          Down                 0.0079099
  1421392_a\_at   Birc3           Baculoviral IAP repeat-containing 3                                               1.68          Down                 0.0047363
  1439327_at      Ccbe1           Collagen and calcium binding EGF domains 1                                        1.70          Down                 0.0161750
  1425092_at      Cdh10           Cadherin 10                                                                       1.55          Down                 0.0017864
  1433956_at      Cdh5            Cadherin 5                                                                        1.63          Down                 0.0036152
  1428574_a\_at   Chn2            Chimerin (chimaerin) 2                                                            1.68          Down                 0.0445669
  1430173_x\_at   Cyp4f16         Cytochrome P450                                                                   1.64          Down                 0.0099976
  1459280_at      D1Ertd185e      DNA segment                                                                       1.71          Down                 0.0239316
  1436480_at      Dpp7            Dipeptidylpeptidase 7                                                             1.61          Down                 0.0365102
  1443772_at      Dzip1           DAZ interacting protein 1                                                         1.56          Down                 0.0054066
  1427462_at      E2f3            E2F transcription factor 3                                                        1.54          Down                 0.0248094
  1416916_at      Elf3            E74-like factor 3                                                                 1.57          Down                 0.0159981
  1437020_at      Ep400           E1A binding protein p400                                                          1.54          Down                 0.0347020
  1445191_at      Exdl1           Exonuclease 3′-5′ domain-like 1                                                   1.97          Down                 0.0053002
  1440063_at      Farsa           Pphenylalanyl-tRNA synthetase                                                     1.64          Down                 0.0250529
  1419378_a\_at   Fxyd2           FXYD domain-containing ion transport regulator 2                                  1.65          Down                 0.0331975
  1437106_at      Kdm5a           Lysine (K)-specific demethylase 5A                                                1.54          Down                 0.0325942
  1428174_x\_at   Khsrp           KH-type splicing regulatory protein                                               1.56          Down                 0.0364211
  1428980_at      Kprp            Keratinocyte expressed                                                            1.71          Down                 0.0279730
  1441526_at      Mbtd1           mbt domain containing 1                                                           1.59          Down                 0.0238720
  1426557_at      Mesp1           Mesoderm posterior 1                                                              1.61          Down                 0.0337495
  1443165_at      Mrps31          Mitochondrial ribosomal protein S31                                               1.52          Down                 0.0362433
  1416839_at      Mut             Methylmalonyl-Coenzyme A mutase                                                   1.67          Down                 0.0387990
  1460159_at      Mysm1           myb-like                                                                          1.85          Down                 0.0334813
  1455343_at      Plekha7         Pleckstrin homology domain containing                                             1.59          Down                 0.0331890
  1460419_a\_at   Prkcb           Protein kinase C, beta                                                            1.95          Down                 0.0010795
  1429474_at      Ptgr2           Prostaglandin reductase 2                                                         1.54          Down                 0.0374520
  1443162_at      Ptpn3           Protein tyrosine phosphatase, non-receptor type 3                                 2.47          Down                 0.0147085
  1427486_at      Ptprb           Protein tyrosine phosphatase, receptor type B                                     1.61          Down                 0.0172879
  1443860_at      Ptprd           Protein tyrosine phosphatase, receptor type D                                     1.70          Down                 0.0254090
  1457488_at      Ralgapb         Ral GTPase activating protein, beta subunit (non-catalytic)                       1.61          Down                 0.0010210
  1429462_at      Slc25a32        Solute carrier family 25                                                          1.66          Down                 0.0135294
  1416854_at      Slc34a2         Solute carrier family 34 (sodium phosphate)                                       1.73          Down                 0.0441978
  1426715_s\_at   Slc46a1         Solute carrier family 46                                                          1.60          Down                 0.0267808
  1451938_a\_at   Sntb1           Syntrophin                                                                        1.55          Down                 0.0125492
  1421472_at      Srm3            Serine/arginine repetitive matrix 3                                               1.61          Down                 0.0277383
  1456363_at      St7l            Supression of tumorigenicity 7-like                                               1.84          Down                 0.0015698
  1451995_at      Taf11           TAF11 RNA polymerase II                                                           1.51          Down                 0.0037954
  1422973_a\_at   Thrsp           Thyroid hormone responsive SPOT14 homolog (Rattus)                                1.61          Down                 0.0480069
  1419949_at      Tmem38b         Transmembrane protein 38B                                                         1.58          Down                 0.0456857
  1436108_at      Txndc9          Thioredoxin domain containing 9                                                   1.53          Down                 0.0196796
  1429971_at      Txnrd2          Thioredoxin reductase 2                                                           1.66          Down                 0.0306703
  1450151_at      Zfp316          Zinc finger protein 316                                                           1.84          Down                 0.0000381

Note: Affymetrix Probe set ID numbers are given; Ddx3y, Eif2s3y, and Uty are represented by multiple probe sets, and 2 probe sets have no annotation. The comparison of transgenic/control indicates elevation or reduction of expression in Hoxd4-transgenic chondrocytes relative to controls. Eighty-five entities (80 genes) are differentially expressed (unpaired *t*-test; fold-change ≥1.5; *P* value \< 0.05) in Hoxd4-transgenic chondrocytes compared with controls.

Cluster analysis (**[Fig. 1B](#fig1-1947603510363005){ref-type="fig"}**) revealed 43 transcripts with moderate expression levels: 33 transcripts with high (red) and 9 transcripts with lower expression levels (blue) in Hoxd4-transgenic chondrocytes and the control group.

Gene expression levels were validated by quantitative RT-PCR for a total of 18 genes, as shown in **[Table 2](#table2-1947603510363005){ref-type="table"}**. Uty (ubiquitously transcribed tetratricopeptide repeat gene, Y-chromosome) was the only gene for which the differential expression detected by microarray experiment was confirmed by RT-PCR when using the criteria of *P* \< 0.05 and fold-change ≥ 1.5. The genes encoding Uty, as well as Eif2s3y (eukaryotic translation initiation factor 2) and Ddx3y (DEAD box polypeptide 3), which are also represented in the gene list of interest (**[Table 3](#table3-1947603510363005){ref-type="table"}**), are known to be Y-linked. Given the unequal representation of Y-linked gene expression between controls and transgenic samples, we hypothesized that male embryos were overrepresented in the Hoxd4-transgenic samples, which was confirmed by PCR on genomic DNA. Such differential expression of Y-linked genes is thus likely an indicator of sex status of the samples and unrelated to overexpression of any Hox transgene.

Differential Expression between Hoxc8- and Hoxd4-Transgenic Mice {#section14-1947603510363005}
----------------------------------------------------------------

The VP16-dependent binary system allowed us to transactivate the Hoxc8 and Hoxd4 transgenes in exactly the same fashion with regard to temporal and tissue specificity, because both transgenes are expressed under control of the same chondrocyte-specific enhancer.^[@bibr10-1947603510363005]^ Thus, we would expect that a comparison between the Hoxc8- and Hoxd4-transgenic cartilage should enable us to determine whether both models of defective cartilage exhibit the same underlying molecular alterations. We therefore compared the data sets from both microarray experiments to screen for differential gene expression between Hoxc8- and Hoxd4-transgenic chondrocytes and their control groups, respectively.

The comparison between the 2 control groups (**[Table 4](#table4-1947603510363005){ref-type="table"}**) revealed only minor differences in gene expression levels, as would be expected given that the genetic background of all samples is the inbred FVB strain. Out of 49 entities with a fold-change ≥ 2, most (39 genes) exhibited higher expression in the controls compared to the Hoxc8-transgenic group, whereas 7 genes exhibited higher expression levels in the controls to the Hoxd4-transgenic animals. The transcript with the highest expression difference, 1446680_at, is lacking any annotation, as do 2 other transcripts in this list. A graphic representation of the respective cluster analysis is shown in **[Figure 2A](#fig2-1947603510363005){ref-type="fig"}**.

###### 

Genes Differentially Expressed between Control Groups to the Hoxc8- and Hoxd-4Transgenic Chondrocytes

  Probe set ID    Gene symbol     Gene title                                                            Fold-change   C~c8~/C~d4~   *P* value
  --------------- --------------- --------------------------------------------------------------------- ------------- ------------- ------------------------------------------------------------------
  1446904_at      4933430H15Rik   RIKEN CDNA 4933430H15 GENE                                            2.20          Up            0.0267147
  1441372_at      5930405F01Rik   RIKEN cDNA 5930405F01 gene                                            2.03          Up            0.0106855
  1459878_a\_at   A430107O13Rik   RIKEN cDNA A430107O13 gene                                            2.05          Up            0.0146135
  1449785_at      AA414993        Expressed sequence AA414993                                           2.23          Up            0.0066515
  1444518_at      Acox1           Acyl-Coenzyme A oxidase 1                                             2.15          Up            0.0427789
  1457548_at      Adamts6         A disintegrin-like and metallopeptidase with thrombospondin motif 6   2.05          Up            0.0048153
  1442331_at      Alas1           Aminolevulinic acid synthase 1                                        2.39          Up            0.0309663
  1442750_at      B3galnt2        UDP-GalNAc:betaGlcNAc beta 1,3-galactosaminyltransferase 2            2.11          Up            0.0003865
  1443837_x\_at   Bcl2            B-cell leukemia/lymphoma 2                                            2.14          Up            0.0278712
  1460005_at      Bod1l           Biorientation of chromosomes in cell division 1-like                  2.59          Up            0.0019409^[a](#table-fn5-1947603510363005){ref-type="table-fn"}^
  1425556_at      Crkrs           Cdc2-related kinase                                                   2.10          Up            0.0212575
  1419209_at      Cxcl1           Chemokine (C-X-C motif) ligand 1                                      2.26          Up            0.0418118^[a](#table-fn5-1947603510363005){ref-type="table-fn"}^
  1443068_at      D130084N16Rik   RIKEN cDNA D130084N16 gene                                            2.03          Up            0.0155479
  1458924_at      D430013B06Rik   RIKEN cDNA D430013B06 gene                                            2.18          Up            0.0038493^[a](#table-fn5-1947603510363005){ref-type="table-fn"}^
  1439972_at      Etnk1           Ethanolamine kinase 1                                                 2.15          Up            0.0072570^[a](#table-fn5-1947603510363005){ref-type="table-fn"}^
  1441543_at      Eya3            Eyes absent 3 homolog (Drosophila)                                    2.20          Up            0.0125155
  1424155_at      Fabp4           Fatty acid binding protein 4                                          2.82          Up            0.0387713
  1459140_at      Fam172a         Family with sequence similarity 172, member A                         2.15          Up            0.0045271
  1450297_at      Il6             Interleukin 6                                                         2.27          Up            0.0181221^[a](#table-fn5-1947603510363005){ref-type="table-fn"}^
  1438519_at      LOC100042938    Hypothetical protein LOC100042938                                     2.93          Up            0.0006803^[a](#table-fn5-1947603510363005){ref-type="table-fn"}^
  1440365_at      Lrrc58          Leucine rich repeat containing 58                                     2.01          Up            0.0024045
  1446680_at      NA              NA                                                                    3.10          Up            0.0048833
  1443267_at      NA              NA                                                                    2.21          Up            0.0058328
  1457020_at      NA              NA                                                                    2.12          Up            0.0491902^[a](#table-fn5-1947603510363005){ref-type="table-fn"}^
  1447863_s\_at   Nr4a2           Nuclear receptor subfamily 4, group A, member 2 (Nurr1)               2.07          Up            0.0356418
  1442700_at      Pde4b           Phosphodiesterase 4B                                                  2.02          Up            0.0129483^[a](#table-fn5-1947603510363005){ref-type="table-fn"}^
  1444817_at      Plekhh2         Pleckstrin homology domain containing                                 2.08          Up            0.0045902
  1444288_at      Pnpt1           Polyribonucleotide nucleotidyltransferase 1                           2.22          Up            0.0026789
  1456506_at      Prpf38b         PRP38 pre-mRNA processing factor 38 domain containing B               2.32          Up            0.0054556
  1456262_at      Rbm5            RNA binding motif protein 5                                           2.13          Up            0.0013445
  1419247_at      Rgs2            Regulator of G-protein signaling 2                                    2.02          Up            0.0149932
  1429810_at      Rictor          RPTOR independent companion of MTOR, complex 2                        2.47          Up            0.0033017
  1459627_at      Sc4mol          Sterol-C4-methyl oxidase-like                                         2.02          Up            0.0150953^[a](#table-fn5-1947603510363005){ref-type="table-fn"}^
  1444811_at      Sec62           SEC62 homolog (S. cerevisiae)                                         2.52          Up            0.0008590^[a](#table-fn5-1947603510363005){ref-type="table-fn"}^
  1444006_at      Setd2           SET domain containing 2                                               2.55          Up            0.0039997
  1441417_at      Stt3a           STT3 homolog A (S. cerevisiae)                                        2.08          Up            0.0039461
  1456717_at      Tead1           TEA domain family member 1                                            2.57          Up            0.0068079^[a](#table-fn5-1947603510363005){ref-type="table-fn"}^
  1440314_at      Trip12          Thyroid hormone receptor interactor 12                                2.27          Up            0.0025044^[a](#table-fn5-1947603510363005){ref-type="table-fn"}^
  1456843_at      Yes1            Yamaguchi sarcoma viral (v-yes) oncogene homolog 1                    2.19          Up            0.0119575
  1441701_at      Zfp148          Zinc finger protein 148                                               3.05          Up            0.0008374
  1457908_at      Zfp407          Zinc finger protein 407                                               2.61          Up            0.0053867
  1442709_at      Zfp521          Zinc finger protein 521                                               2.21          Up            0.0085250
  1425092_at      Cdh10           Cadherin 10                                                           2.27          Down          0.0412955
  1453931_at      Col14a1         Collagen, type XIV, alpha 1                                           2.19          Down          0.0310586
  1430369_at      Epb4.1          Erythrocyte protein band 4.1                                          2.17          Down          0.0019551
  1443716_at      LOC100039210    Hypothetical protein LOC100039210                                     2.70          Down          0.0227941
  1438239_at      Mid1            Midline 1                                                             2.66          Down          0.0023385
  1455591_at      Zfp618          Zinc finger protein 618                                               2.01          Down          0.0040700
  1453051_at      Zkscan1         Zinc finger with KRAB and SCAN domains 1                              2.13          Down          0.0003634

Note: The microarray results were compared between the respective control samples (*n* = 4 each) using the same criteria as before (unpaired *t*-test; fold-change ≥1.5; *P* value \< 0.05); this listing contains 49 probe sets with an apparent expression difference greater than 2-fold. Three probe sets lacked any annotation.

Probe sets that are also represented after comparative analysis of Hoxc8- and Hoxd4-transgenic chondrocytes (**[Table 5](#table5-1947603510363005){ref-type="table"}**).

![Differential gene expression between control groups and transgenic groups. Entities revealed using the unpaired *t*-test (present or marginal flag in 5 of 8 samples, fold-change ≥ 1.5 and *P* value \< 0.05) were clustered according to the K-means algorithm with Euclidean distance metric. (**A**) Cluster analysis for 445 entities with significantly different expression levels between control groups to the transgenic conditions; 387 entities had a differential in expression between 1.5- and 2-fold. (**B**) Cluster analysis for 532 entities with significantly different expression levels in comparison with Hoxc8-transgenic versus Hoxd4-transgenic samples; 460 entities had a differential in expression between 1.5- and 2-fold.](10.1177_1947603510363005-fig2){#fig2-1947603510363005}

When we compared the group of Hoxc8-transgenic samples to the group of Hoxd4-transgenic samples, this yielded 72 entities with differential expression greater than 2-fold (**[Table 5](#table5-1947603510363005){ref-type="table"}**). Three probe sets lack annotation, and several genes (Mt1: metallothionein 1, Akap9: kinase anchor protein 9, and Ddit3: DNA-damage inducible transcript 3) are represented with 2 probe sets. Only 7 of the transcripts on this list exhibited decreased expression levels in Hoxc8-transgenic samples, whereas the majority (59 genes) displayed elevated expression in Hoxc8-transgenic animals. Most notably, Xist (inactive X-specific transcript) levels were higher in the group of Hoxc8-transgenic samples, likely reflecting a higher ratio of female-derived samples as compared with the Hoxd4-transgenic condition, consistent with elevated expression of Y-linked genes in the Hoxd4-transgenic samples. **[Figure 2B](#fig2-1947603510363005){ref-type="fig"}** is a graphic representation of the corresponding cluster analysis.

###### 

Genes Differentially Expressed between Hoxc8- and Hoxd4-Transgenic Chondrocytes

  Probe set ID    Gene symbol     Gene title                                                       Fold-change   c8-transg/d4-transg   *P* value
  --------------- --------------- ---------------------------------------------------------------- ------------- --------------------- ------------------------------------------------------------------
  1443584_at      1110028C15Rik   RIKEN cDNA 1110028C15 gene                                       2.10          Up                    0.0246180
  1432600_at      2310061A09Rik   RIKEN cDNA 2310061A09 gene                                       2.04          Up                    0.0120357
  1437110_at      2810474O19Rik   RIKEN cDNA 2810474O19 gene                                       2.03          Up                    0.0191083
  1453595_at      2900064B18Rik   RIKEN cDNA 2900064B18 gene                                       2.45          Up                    0.0271002
  1441331_at      A230061C15Rik   RIKEN cDNA A230061C15 gene                                       2.01          Up                    0.0092051
  1439143_at      A930018M24Rik   RIKEN cDNA A930018M24 gene                                       2.91          Up                    0.0048276
  1446068_at      Adk             Adenosine kinase                                                 2.23          Up                    0.0243666
  1455151_at      Akap9           A kinase (PRKA) anchor protein (yotiao) 9                        2.20          Up                    0.0276093
  1437082_at      Akap9           A kinase (PRKA) anchor protein (yotiao) 9                        2.15          Up                    0.0430726
  1434988_x\_at   Aldh2           Aldehyde dehydrogenase 2                                         2.00          Up                    0.0050611
  1420947_at      Atrx            Alpha thalassemia/mental retardation syndrome X-linked homolog   2.16          Up                    0.0166582
  1439216_at      BB211804        Expressed sequence BB211804                                      2.01          Up                    0.0106094
  1458163_at      BC066028        cDNA sequence BC066028                                           4.00          Up                    0.0126564
  1440770_at      Bcl2            B-cell leukemia/lymphoma 2                                       2.16          Up                    0.0007920
  1460005_at      Bod1l           Biorientation of chromosomes in cell division 1                  2.91          Up                    0.0009071^[a](#table-fn7-1947603510363005){ref-type="table-fn"}^
  1456050_at      C80998          Expressed sequence C80998                                        2.19          Up                    0.0019366
  1453319_at      Ccar1           Cell division cycle and apoptosis regulator 1                    2.58          Up                    0.0046564
  1445843_at      Chd2            Chromodomain helicase DNA binding protein 2                      2.18          Up                    0.0203581
  1441726_at      Clasp2          CLIP associating protein 2                                       2.16          Up                    0.0430622
  1417496_at      Cp              Ceruloplasmin                                                    2.10          Up                    0.0467060
  1437372_at      Cpsf6           Cleavage and polyadenylation specific factor 6                   2.11          Up                    0.0192667
  1419038_a\_at   Csnk2a1         Casein kinase 2                                                  2.37          Up                    0.0013194
  1419209_at      Cxcl1           Chemokine (C-X-C motif) ligand 1                                 2.08          Up                    0.0235844^[a](#table-fn7-1947603510363005){ref-type="table-fn"}^
  1458924_at      D430013B06Rik   RIKEN cDNA D430013B06 gene                                       3.61          Up                    0.0421971^[a](#table-fn7-1947603510363005){ref-type="table-fn"}^
  1454869_at      Dcaf12l1        DDB1 and CUL4 associated factor 12-like 1                        3.59          Up                    0.0499441
  1442329_at      Dclre1a         DNA cross-link repair 1A                                         2.30          Up                    0.0022126
  1443897_at      Ddit3           DNA-damage inducible transcript 3                                2.13          Up                    0.0179668
  1417516_at      Ddit3           DNA-damage inducible transcript 3                                2.07          Up                    0.0324307
  1439972_at      Etnk1           Ethanolamine kinase 1                                            2.36          Up                    0.0077480^[a](#table-fn7-1947603510363005){ref-type="table-fn"}^
  1443628_at      Fam82b          Family with sequence similarity 82, member B                     2.14          Up                    0.0089534
  1441548_at      Frmd4b          FERM domain containing 4B                                        2.15          Up                    0.0027981
  1419378_a\_at   Fxyd2           FXYD domain-containing ion transport regulator 2                 2.58          Up                    0.0074027
  1429257_at      Gtl2            GTL2                                                             2.03          Up                    0.0174762
  1450297_at      Il6             Interleukin 6                                                    3.03          Up                    0.0060546^[a](#table-fn7-1947603510363005){ref-type="table-fn"}^
  1438519_at      LOC100042938    Hypothetical protein LOC100042938                                2.50          Up                    0.0018819^[a](#table-fn7-1947603510363005){ref-type="table-fn"}^
  1446316_at      Lpin2           Lipin 2                                                          2.68          Up                    0.0403329
  1452592_at      Mgst2           Microsomal glutathione S-transferase 2                           2.50          Up                    0.0052901
  1451612_at      Mt1             Metallothionein 1                                                2.25          Up                    0.0304642
  1422557_s\_at   Mt1             Metallothionein 1                                                2.01          Up                    0.0252146
  1428942_at      Mt2             Metallothionein 2                                                2.20          Up                    0.0241249
  1429013_at      Mtap7d2         MAP7 domain containing 2                                         2.25          Up                    0.0085073
  1440708_at      Myh9            Myosin                                                           2.12          Up                    0.0422888
  1418366_at      NA              NA                                                               2.09          Up                    0.0224857
  1446730_at      NA              NA                                                               3.42          Up                    0.0236191
  1457020_at      NA              NA                                                               2.21          Up                    0.0399145^[a](#table-fn7-1947603510363005){ref-type="table-fn"}^
  1457208_at      Nfxl1           Nuclear transcription factor                                     2.81          Up                    0.0056797
  1430309_at      Nipbl           Nipped-B homolog (Drosophila)                                    2.02          Up                    0.0056786
  1419107_at      Ophn1           Oligophrenin 1                                                   2.77          Up                    0.0162735
  1441026_at      Parp4           Poly (ADP-ribose) polymerase family                              2.08          Up                    0.0060589
  1442700_at      Pde4b           Phosphodiesterase 4B                                             2.14          Up                    0.0027187^[a](#table-fn7-1947603510363005){ref-type="table-fn"}^
  1446490_at      Ptbp2           Polypyrimidine tract binding protein 2                           2.09          Up                    0.0003002
  1447164_at      Rlf             Rearranged L-myc fusion sequence                                 2.21          Up                    0.0029808
  1437224_at      Rtn4            Reticulon 4                                                      2.21          Up                    0.0016998
  1459627_at      Sc4mol          Sterol-C4-methyl oxidase-like                                    2.06          Up                    0.0181274^[a](#table-fn7-1947603510363005){ref-type="table-fn"}^
  1444811_at      Sec62           SEC62 homolog (S. cerevisiae)                                    2.84          Up                    0.0030046^[a](#table-fn7-1947603510363005){ref-type="table-fn"}^
  1421564_at      Serpina3c       Serine (or cysteine) peptidase inhibitor                         2.26          Up                    0.0199104
  1459571_at      Sh3bgrl         SH3-binding domain glutamic acid-rich protein like               3.81          Up                    0.0290655
  1456717_at      Tead1           TEA domain family member 1                                       2.43          Up                    0.0040962^[a](#table-fn7-1947603510363005){ref-type="table-fn"}^
  1423405_at      Timp4           Tissue inhibitor of metalloproteinase 4                          2.45          Up                    0.0038079
  1440314_at      Trip12          Thyroid hormone receptor interactor 12                           2.05          Up                    0.0418329^[a](#table-fn7-1947603510363005){ref-type="table-fn"}^
  1447266_at      Utp18           UTP18                                                            2.09          Up                    0.0005509
  1434433_x\_at   Wdr61           WD repeat domain 61                                              2.00          Up                    0.0061046
  1436746_at      Wnk1            WNK lysine deficient protein kinase 1                            2.01          Up                    0.0223951
  1427262_at      Xist            Inactive X specific transcripts                                  22.35         Up                    0.0431562
  1436429_at      Zfp606          Zinc finger protein 606                                          2.87          Up                    0.0018548
  1435050_at      D10Bwg1379e     DNA segment                                                      2.05          Down                  0.0088644
  1445605_s\_at   Fam135a         Family with sequence similarity 135, member A                    2.23          Down                  0.0019277
  1419139_at      Gdf5            Growth differentiation factor 5                                  2.59          Down                  0.0425737
  1444657_at      N4bp2           NEDD4 binding protein 2                                          2.43          Down                  0.0005223
  1415893_at      Sgpl1           Sphingosine phosphate lyase 1                                    2.25          Down                  0.0139590
  1429979_a\_at   Slc38a10        Solute carrier family 38, member 10                              2.11          Down                  0.0116045
  1419913_at      Strap           Serine/threonine kinase receptor associated protein              2.14          Down                  0.0332865

Note: Comparison of microarray results between Hoxc8- and Hoxd4-transgenic samples (unpaired *t*-test; fold-change ≥1.5; *P* value \< 0.05); 72 entities exhibit expression differences of greater than 2-fold. Akap9, Ddit3, and Mt1 are represented by multiple probe sets; 3 probe sets lacked annotations.

Probe sets also represented as differentially expressed in the comparison of controls to these transgenic samples (**[Table 4](#table4-1947603510363005){ref-type="table"}**).

It is of interest to note here that 12 differentially expressed entities were identified both in the comparison of samples between the transgenic conditions and in the comparison between the control groups. These entities are all decreased in expression levels in samples from the Hoxd4-transgenic animals and their littermate controls, regardless of whether the Hoxd4 transgene is expressed (as in mice doubly transgenic for TA and TR transgenes, the Hoxd4-transgenics) or not (as in the controls). This finding would suggest that progeny in such litters may be different from those in the Hoxc8-transgene--related crosses. Indeed, in contrast to the Hoxc8-transgene, the Hoxd4-transgene is inherited only through the female germline (C. Kappen et al., unpublished data). The deregulation of these 12 entities in all progeny (controls and transgenics) from Hoxd4-transgenic dams could thus be associated with a transgene-locus--specific maternal effect but is likely independent of transgene expression in the progeny cartilage.

Discussion {#section15-1947603510363005}
==========

This article reports genomewide expression profiling in primary chondrocytes of Hoxc8- and Hoxd4-transgenic mice. Our aim was to use differential expression as a means to identify genes whose transcription may be under control of Hox transcription factors. Among such targets of the Hox transcription factors in cartilage could be new genes that might play important roles in cartilage development.

Using the Affymetrix microarray platform, we identified 57 genes with differential expression in Hoxc8-transgenic chondrocyctes relative to controls. Of particular interest are the elevated expression levels of Replication initiator 1 (Repin1), Topoisomerase 1 (Top1), and Clip associating protein 2 (Clasp2), an M-phase expressed protein, and the decreased expression of Stag1, an inhibitor of cell growth. These results are consistent with the accumulation of proliferating cells in Hoxc8-transgenic cartilage^[@bibr10-1947603510363005]^ and with a role for Hoxc8 in regulating cell cycle of chondrocytes in M-phase.^[@bibr11-1947603510363005]^ The lower expression level of Inversin, which acts in the PCP pathway, is consistent with our earlier finding of reduced Wnt5a expression in Hoxc8-transgenic chondrocytes.^[@bibr16-1947603510363005]^ In Hoxd4-transgenic chondrocytes, we identified 80 deregulated genes; the majority of these genes had lower expression compared with controls. Elevated expression was found for 2 genes with roles in cell proliferation, M-phase phosphoprotein 1 (Mphos1) and Protein phosphatase 2A (PP2A), which controls the G2/M checkpoint of the cell cycle. Antagonist of mitotic exit network 1 (Amn1), which is required for progression through the cell cycle, displays reduced expression in Hoxd4-transgenic chondrocytes. These results support the notion that cell cycle regulation and cell proliferation are altered in Hoxd4-transgenic cartilage, just as in Hoxc8-transgenic chondrocytes. However, overexpression of Hoxc8 in chondrocytes appears to deregulate a different repertoire of genes compared with Hoxd4 overexpression. We therefore conclude that the 2 transcription factors affect proliferation and/or differentiation of chondrocytes through different molecular mechanisms. This is further supported by direct comparison of Hoxd4-transgenic to Hoxc8-transgenic chondrocytes; the latter exhibit higher expression of the apoptosis regulators Bcl2 and Ccar1, prompting the speculation that, in addition to different Wnt signaling pathway activities,^[@bibr16-1947603510363005]^ apoptosis regulation could be different between the 2 transgenic paradigms.

For the validation by quantitative RT-PCR, 18 transcripts were chosen from each transgenic condition, equally distributed over the range of expression levels. Statistical significance for differences between groups could not be confirmed in these assays. One technical limitation may be the small sample size of *n* = 6 per group. This would be particularly limiting if overexpression of the respective transgene induces a wider spread of gene expression levels (i.e., greater variability in gene expression) within the transgenic group compared with controls.

To investigate the extent of variation in expression levels on Hox transgene overexpression, raw signal intensity values from the microarray chips were obtained. Only entities with a "present" flag were included in this analysis. For all gene expression measurements, the coefficient of variation (CV) was calculated for the groups of control samples and groups of transgenic samples, independently. This was done by dividing the standard deviation of each individual measurement from the average by the mean over 4 samples; thus, variation is expressed in relation to the absolute expression level for each gene. The resulting values were grouped by *P* value for the comparison (*P* \< 0.05 = significant, or *P* ≥ 0.05 = not significant) between controls and transgenic samples for each gene and sorted in descending order within the group of entities with significantly different gene expression levels and the group of nonsignificant comparisons, separately (**[Fig. 3A](#fig3-1947603510363005){ref-type="fig"}**). Greater variation, as represented by higher CV values on the y-axis, was found for the group of entities with *P* values ≥ 0.05, as would be expected (large within-group variations tend to produce nonsignificant *P* values in between-group comparisons). This applies to the CV values of control samples, as well as samples in the Hoxc8-transgenic group (**[Fig. 3B](#fig3-1947603510363005){ref-type="fig"}**), and no difference in variation between control and transgenic group was detected for genes that are not differentially expressed (*P* ≥ 0.05) between the 2 conditions. There was also no difference between controls and transgenic samples in the distribution of coefficients for the entities exhibiting differential expression (*P* \< 0.05). This argues against the possibility that transgene overexpression increases overall variability of gene expression levels. Applied to the Hoxd4-transgenic condition (**[Figs. 3 C](#fig3-1947603510363005){ref-type="fig"} and [D](#fig3-1947603510363005){ref-type="fig"}**), this type of analysis yielded the same conclusion, that is, lack of evidence for greater variability upon transgene overexpression. It should be noted, however, that this analysis is limited by the fact that the group sizes for *P* ≥ 0.05 and *P* \< 0.05 are necessarily different. Furthermore, we did not find differences in variation between control and transgenic samples when we applied these calculations to gene expression measurements (in form of ΔCt values) obtained from the quantitative RT-PCR assays (**[Figs. 3 E](#fig3-1947603510363005){ref-type="fig"} and [F](#fig3-1947603510363005){ref-type="fig"}**).

![Variability of gene expression levels in Hoxc8- and Hoxd4-transgenic chondrocytes. Only entities with a "present" flag were included in the calculation. The microarray detection signals were averaged over the 4 control samples and the standard deviation calculated. The standard deviation was then divided by the mean to obtain the coefficient of variation; values were sorted in descending order in both groups (*P* \< 0.05 and *P* ≥ 0.05). Parallel calculations were done for the transgenic animals. As expected, we found higher variability of expression levels in samples with *P* values greater than 0.05 for Hoxc8 animals relative to samples (**C, D**). For polymerase chain reaction (PCR)--validated gene expression levels, calculations were performed as described above using ΔCt values. (**E, F**) Variability in relative expression levels (measured by reverse transcriptase PCR) in the comparison between control (*n* = 6) and Hoxc8-transgenic samples (*n* = 6) and between controls and Hoxd4-transgenic samples, respectively.](10.1177_1947603510363005-fig3){#fig3-1947603510363005}

A 2nd possible technical reason for the lack of congruence of the RT-PCR results with the microarray data could be the location of the PCR amplicon for each gene. The microarray probes are designed to sample the far 3′ end of the gene transcript, whereas we designed primer pairs to span exon-exon boundaries, which are located further toward the 5′ end of the transcript.

A 3rd possibility is that the mRNA abundance in the samples is at the lower level of detection by RT-PCR. However, we selected both high- and low-abundance transcripts for our validation experiments and should have been able to detect such a phenomenon.

A 4th possibility bearing on the outcome of the PCR assays is the choice of reference gene. Because expression measurements for each gene of interest are normalized to Gapdh expression level, any changes in Gapdh expression as a consequence of Hox transgene overexpression would have a profound impact on the results. However, signals for Gapdh expression were not different between any of the experimental groups in the microarray assays. Furthermore, the levels of Gapdh expression detected by quantitative RT-PCR were also within a narrow range for all groups (Ct~Gapdh~ = 18.89 ± 0.52 for Hoxc8-transgenic samples versus Ct~Gapdh~ = 18.79 ± 0.68 for controls, and Ct~Gapdh~ = 18.39 ± 0.69 for Hoxd4-transgenic samples versus Ct~Gapdh~ = 18.29 ± 0.66 for controls). These data confirm Gapdh as a suitable reference gene for our RT-PCR assays.

In earlier studies, we performed targeted gene expression studies by quantitative RT-PCR on 23 folate metabolism genes^[@bibr14-1947603510363005]^ and 37 cartilage developmental genes^[@bibr16-1947603510363005]^ in primary chondrocytes from Hoxc8- and Hoxd4-transgenic animals, respectively. The choice of targets for this prior work was guided by evidence from the literature, and assays were performed prior to the microarray analyses reported here. Among the 60 genes thus investigated, 9 genes (Bmp4, Fgf8, Fgf10, Mmp9, Mmp13, Nos3, Timp3, Wnt3a, and Wnt5a) exhibited differential expression in Hoxc8-transgenic cartilage and 4 genes (Fgfr3, Ihh, Mmp8, and Wnt3a) in Hoxd4-transgenic samples.^[@bibr16-1947603510363005]^ Upon retroactive inspection of these 60 genes in our microarray analyses, we found that they are either not represented on the arrays, did not pass the signal requirement of "present" or "marginal" in 5 of 8 samples or more, or did not pass cutoff criteria for fold-change and *P*-value levels. The current study adds an additional 18 genes per condition to the list of genes whose expression was not altered by Hox transgene overexpression. Thus, of 78 candidate genes measured by RT-PCR, 9 genes (11.54%) exhibited altered levels in Hoxc8-transgenic chondrocytes and 4 (5.1%) in Hoxd4-transgenic cells. Likewise, the results from microarray assays presented here identify only a relatively small (less than 100 per condition) number of genes with differential expression in transgenic chondrocytes. Similarly low yields were reported for cDNA microarray studies on Hoxd10 mutant spinal cord cells, which confirmed 9 genes by PCR of the 69 identified from the arrays (13%).^[@bibr17-1947603510363005]^ Even so, this low number of potential transcriptional targets is perplexing, given the serious cartilage differentiation defects in the Hoxc8- and Hoxd4-transgenic animals.^[@bibr8-1947603510363005],[@bibr10-1947603510363005]^ We also showed earlier, by RT-PCR assays with primer sets that amplify a part of the coding sequence, that the transgenes are overexpressed on average by 4.6-fold (in the case of Hoxc8) and close to 15-fold (for Hoxd4) when compared with respective littermate controls.^[@bibr14-1947603510363005]^ In the microarray assays employed here, only 3′ regions of Hoxc8 and Hoxd4 are sampled. However, the native 3′ regions of Hoxc8 and Hoxd4 are substituted by heterologous (SV40-derived) noncoding sequences in the Hoxc8- and Hoxd4-transgenes, respectively.^[@bibr13-1947603510363005]^ A number of conceivable biological scenarios may limit our ability to define transcriptional consequences of Hox transgene overexpression in chondrocytes by the gene expression--profiling approaches we have employed:

1.  The actions of the overexpressed Hox transcription factors are not occurring in chondrocytes themselves but nonautonomously through undefined mechanisms. This is unlikely, given that we have shown the transgenes to be expressed in developing cartilage by virtue of VP16-mediated transactivation.^[@bibr10-1947603510363005],[@bibr13-1947603510363005],[@bibr14-1947603510363005]^ We have also demonstrated that knockdown of Hoxc8 expression affects the proliferation and cell cycle progression of primary chondrocytes *in vitro*,^[@bibr11-1947603510363005]^ implicating a cell-autonomous action for Hoxc8. It is nevertheless possible that the fraction of cells with Hox transgene overexpression is rather small in the rib cages from which the chondrocytes were prepared, and thus, strong effects in transgene-expressing cells could be diluted by a larger fraction of unaffected cells; contamination with nonchondrogenic cells, however, is unlikely.^[@bibr15-1947603510363005]^ Hox transgene overexpression^[@bibr10-1947603510363005]^ is expected to be greatest in immature and proliferating cartilage precursor cells (C. Kappen unpublished), and presently, we do not have detailed information on the relative proportion of such cells versus more mature chondrocytes in our samples.

2.  The time point of sampling, embryonic day 18.5, might affect the outcome of this study as well. Chondrocyte maturation is a continuous process commencing from the appearance of chondrogenic condensations at E12.5, and the Hox transgenes are activated at this stage and even earlier.^[@bibr7-1947603510363005],[@bibr10-1947603510363005],[@bibr12-1947603510363005],[@bibr18-1947603510363005]^ Thus, if the major transcriptional effects of transgene overexpression occur earlier than E18.5, the altered expression of Hox target genes may not be maintained into later time points. Apart from the measurements of elevated expression of the transgenes themselves,^[@bibr14-1947603510363005]^ we have previously demonstrated that some genes are indeed aberrantly expressed in Hox transgenic primary chondrocytes prepared at E18.5^[@bibr16-1947603510363005]^; these genes are known to be involved in cartilage development (see above) and are currently under investigation in the cartilage defects in our Hox transgenic paradigms. Nonetheless, it may be necessary to better define the critical time windows of Hox gene actions in the transgenic cartilage and extend the analysis to such time points.

3.  The action of overexpressed Hox transcription factors in developing cartilage may not be primarily at the transcriptional level but through protein-protein interactions, which in turn may be involved in regulating chondrocyte proliferation and/or differentiation. Interactions with protein cofactors are thought to modulate the affinity and specificity of DNA binding by Hox proteins. Meis and Pbx are the best-studied Hox cofactors in mammals^[@bibr19-1947603510363005]-[@bibr21-1947603510363005]^; they form stable heterodimers that bind DNA cooperatively.^[@bibr22-1947603510363005]-[@bibr24-1947603510363005]^ Both Hox and Pbx genes have been implicated in cell proliferation in leukemia^[@bibr25-1947603510363005]-[@bibr31-1947603510363005]^ as well as in skeletal development.^[@bibr32-1947603510363005]-[@bibr35-1947603510363005]^ Thus, in cartilage differentiation, the role of Hox transcription factors is likely to be modulated by protein interactions as well, and such interactions may even supersede transcriptional activity. Recently emerging evidence implicates the Smads, which are known to play roles in BMP and Tgfβ signal transduction, as another class of interactors with Hox proteins in various tissue systems.^[@bibr36-1947603510363005]-[@bibr39-1947603510363005]^ However, the role of such interactions in cartilage development under conditions of Hoxc8 or Hoxd4 overexpression remains to be investigated.

Intriguingly, the detrimental effects of Hox transgene overexpression can be ameliorated by supplementation of folate to the maternal diet,^[@bibr8-1947603510363005]^ indicating that at least some of the cellular abnormalities are reversible. This is further highlighted by our finding that chondrocytes from Hoxc8-transgenic mice, when placed into primary cell culture, are able to proliferate and differentiate apparently normally.^[@bibr15-1947603510363005]^ Thus, the *in vivo* conditions in the transgenic cartilage contribute to the action of overexpressed Hox transcription factors, possibly through cell communication, signaling, or cell-matrix interactions. The nutritional and cellular context may also influence the propensity for cartilage defects on Hox transcription factor misexpression. The genes we have identified in this and our earlier studies will help us elucidate the molecular and cellular basis for proliferation and differentiation defects in Hox transgenic cartilage.

Conclusions {#section16-1947603510363005}
===========

We used genomewide expression profiling to identify genes with altered expression in primary chondrocytes from transgenic mice with overexpression of Hoxc8 and Hoxd4, respectively. In each transgenic paradigm, genes were found misexpressed that are consistent with the interpretation of altered cell proliferation in transgenic cartilage. Intriguingly, the repertoires of differentially expressed genes did not overlap between both conditions, indicating that the 2 Hox transcription factors employ distinct molecular mechanisms in the pathogenesis of defective cartilage. The relatively low number of independently validated misregulated transcripts, however, suggests that the phenotypic abnormalities may also be mediated by nontranscriptional mechanisms downstream of Hox transgene overexpression in developing cartilage.
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